# EDGAR Filing Document

**Accession Number:** 0002101709
**File Stem:** 0001104659-26-007047
**Filing Date:** 2026-1
**Character Count:** 11434
**Document Hash:** a0f96f01af5a52dd35013b03d4d9310e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-007047.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0001104659-26-007047

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260127

**DATE AS OF CHANGE**: 20260127

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zura Bio Ltd
- **CENTRAL INDEX KEY:** 0001855644
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92696
- **FILM NUMBER:** 26567120

**BUSINESS ADDRESS:**
- **STREET 1:** 4225 EXECUTIVE SQUARE
- **STREET 2:** SUITE 600
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** 858-247-0520

**MAIL ADDRESS:**
- **STREET 1:** 4225 EXECUTIVE SQUARE
- **STREET 2:** SUITE 600
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JATT Acquisition Corp
- **DATE OF NAME CHANGE:** 20210407
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Athanor Capital
- **CENTRAL INDEX KEY:** 0002101709

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 2578 BROADWAY
- **STREET 2:** #593
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10025
- **BUSINESS PHONE:** 808-868-5193

**MAIL ADDRESS:**
- **STREET 1:** 2578 BROADWAY
- **STREET 2:** #593
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10025

## Exhibit 99.1

**EXHIBIT 1**

**JOINT FILING AGREEMENT**

**PURSUANT TO RULE 13d-1(k)**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning such person contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1), the undersigned further agree that only one statement containing the information required by Schedule 13D need be filed with respect to the beneficial ownership of securities reported therein, and that this Joint Filing Agreement shall be filed as an exhibit to such Schedule 13D.

The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

Date: January 26, 2026

---

| | |
|:---|:---|
| Athanor Capital | Athanor Capital |
| By: | /s/ *Parvinder Thiara* |
| Name: | Parvinder Thiara |
| Title: | Director |

---

---

| | |
|:---|:---|
| UGS Capital LLC | UGS Capital LLC |
| By: | /s/ *Parvinder Thiara* |
| Name: | Parvinder Thiara |
| Title: | Manager |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Zura Bio Limited**

*(Name of Issuer)*

**Class A Ordinary Shares, par value $0.0001 per share**

*(Title of Class of Securities)*

**G9TY5A101**

*(CUSIP Number)*

**Athanor Capital**<br>2578 Broadway<br>Suite #593<br>New York NY 10025<br>(345) 936 2455

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/23/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G9TY5A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Athanor Capital** | Name of reporting person<br>**Athanor Capital** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11581402.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11581402.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**11581402.00** | Aggregate amount beneficially owned by each reporting person<br>**11581402.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.7%** | Percent of class represented by amount in Row (11)<br>**15.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **G9TY5A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**UGS Capital LLC** | Name of reporting person<br>**UGS Capital LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11581402.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11581402.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**11581402.00** | Aggregate amount beneficially owned by each reporting person<br>**11581402.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.7%** | Percent of class represented by amount in Row (11)<br>**15.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Ordinary Shares, par value $0.0001 per share

**(b) Name of Issuer:**
Zura Bio Limited

**(c) Address of Issuer's Principal Executive Offices:**
1489 W. Warm Springs Rd. #110, Henderson, NV, 89014

**Item 4. Purpose of Transaction**

The securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through 4(j) of Schedule 13D.

The Reporting Persons may, from time to time, review their investment in the Issuer and may engage in discussions with management or the board of directors of the Issuer regarding the Issuer's business, operations and prospects, subject to applicable law. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or whether to adopt plans or proposals of the type specified above or otherwise.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date of this Schedule 13D, the Reporting Persons may be deemed to beneficially own an aggregate of 11,581,402 Class A Ordinary Shares of the Issuer, representing approximately 15.7% of the Issuer's outstanding Class A Ordinary Shares.

The percentage ownership reported herein is based on 73,680,710 Class A Ordinary Shares outstanding, as advised to the Reporting Persons by the Issuer as of the filing date of the Prior Schedule 13G.

**(b)**
The information set forth in Rows 7 through 10 of the cover pages of this Schedule 13D with respect to the number of Class A Ordinary Shares as to which each of the Reporting Persons has sole or shared power to vote or to direct the vote and sole or shared power to dispose of or to direct the disposition is incorporated herein by reference.

Athanor Capital directly holds 11,581,402 Class A Ordinary Shares and has shared power to vote and shared power to dispose of such shares. UGS Capital LLC may be deemed to beneficially own such shares by virtue of its relationship with Athanor Capital and has shared power to vote and shared power to dispose of such shares. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

**(c)**
The information set forth in Item 3 hereof is incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set form in Item 3 hereof is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Athanor Capital

**Signature:** /s/ Parvinder Thiara

**Name/Title:** Parvinder Thiara/Director

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** UGS Capital LLC

**Signature:** /s/ Parvinder Thiara

**Name/Title:** Parvinder Thiara/Director

**Date:** 01/27/2026